BIODESIX INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M |
| Operating income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$40.9M |
| Operating expenses | $116.4M | $105.8M | $90.4M | $88.8M | $95.4M |
| Cash from operations | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$28.2M |
| Capital expenditure | $259,000 | $3.2M | $22.9M | $3.3M | $2.2M |
| Free cash flow | -$23.5M | -$51.9M | -$45.8M | -$48.3M | -$30.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $87.5M | $97.2M | $99.1M | $92.9M | $76.1M |
| Total liabilities | $89.9M | $76.4M | $94.5M | $72.3M | $56.4M |
Shares outstanding 10.1M · Free float 68.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.